Pharmacogenetics of nevirapine-associated hepatotoxicity: An adult AIDS Clinical Trials Group Collaboration

Clinical Infectious Diseases

Volumn 43, Issue 6, 2006, Pages 783-786

  Haas, David W ^a,g   Bartlett, John A ^b   Andersen, Janet W ^d   Sanne, Ian ^f   Wilkinson, Grant R ^a   Hinkle, John ^c   Rousseau, Franck ^c   Ingram, Christiana D ^a   Shaw, Audrey ^c   Lederman, Michael M ^e   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GILEAD SCIENCES INC   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; DNA; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENES, MDR; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LIVER; LIVER DISEASES; MALE; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA;

EID: 33748328070     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/507097     Document Type: Article

References (12)

1. Stormer E, von Moltke LL, Perloff MD, et al. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19:1038-45.
2. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-6.
3. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
4. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C→T affects mRNA stability. Pharmacogenet Genomics 2005; 15:693-704.
5. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
6. Colombo S, Soranzo N, Rotger M, et al. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genomics 2005; 15:599-608.
7. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931-42.
8. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15:1-5.
9. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-9.
10. Almond LM, Edirisinghe D, Dalton M, et al. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther 2005; 78:132-42.
11. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T cell counts. AIDS 2005; 19:97-9.
12. Haas DW, Ritchie MD, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 2005; 43:779-82 (in this issue).